tradingkey.logo

D&D Pharmatech's DD01 Cuts Liver Fat, Boosts Liver & Metabolic Health in Phase 2 MASH Trial

ReutersJun 16, 2025 10:03 AM

- DND Pharmatech Inc 347850.KQ:

  • D&D PHARMATECH ANNOUNCES POSITIVE PHASE 2 RESULTS FOR DD01 IN MASH WITH ROBUST REDUCTIONS IN LIVER FAT ACCOMPANIED BY IMPROVEMENTS IN LIVER AND METABOLIC HEALTH

  • D&D PHARMATECH ANNOUNCES POSITIVE PHASE 2 RESULTS FOR DD01 IN MASH WITH ROBUST REDUCTIONS IN LIVER FAT ACCOMPANIED BY IMPROVEMENTS IN LIVER AND METABOLIC HEALTH

  • DND PHARMATECH INC - 75.8% OF DD01-TREATED SUBJECTS ACHIEVED AT LEAST 30% REDUCTION IN LIVER FAT

  • DND PHARMATECH INC - DD01 TREATMENT ASSOCIATED WITH 62.3% RELATIVE REDUCTION IN LIVER FAT

  • DND PHARMATECH INC - DD01 WELL TOLERATED WITH MILD TO MODERATE GI SIDE EFFECTS

  • DND PHARMATECH INC - DD01 TREATMENT RESULTED IN SIGNIFICANT REDUCTIONS IN HBA1C AND BODY WEIGHT

  • DND PHARMATECH INC - ONLY 3 SUBJECTS DISCONTINUED DD01 TREATMENT DUE TO GI SIDE EFFECTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI